Amneal Pharmaceuticals, Inc.

NASDAQ:AMRX

Drug Manufacturers - Specialty & Generic

Healthcare
$21.88 -0.90%

-$0.15 today

Market cap
$7.62B
Beta
1.32
P/E (TTM)
43.4
EPS (TTM)
$0.37
52W Low $7.67High $16.61

Volume 1.91M

Average 1.75M

AMRX EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Amneal Pharmaceuticals, Inc.NASDAQ: AMRX

EBITDA · Q2 FY2026 · quarter ended Jun 2026

EBITDA grows, but more slowly than its trailing trend

Q2 FY2026 EBITDA of $193.78M rose 9.5% year over year, behind the +11.7% change in trailing-twelve-month EBITDA. Sequentially, it rose 4.1% from the prior quarter. Over 3 fiscal years it compounded at +11.1% a year.

Context

  • EBITDA amounted to 20.0% of revenue in FY2025, up 4.3 pp from a year earlier.
  • EBITDA increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 5 analysts of $945.42M (+56.6%) for the fiscal year ending Dec 2026, a step up from the +37.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$193.78M+4.1% QoQ
Last fiscal yearDec 2025
$603.87M+37.3% YoY
LTMJun 2026
$652.2M+11.7% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+9.5%+106.0%+96.5 pp
1 year+37.3%+56.6%+19.2 pp
3-year CAGR+11.1%+25.1%+14.0 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
603.87M USD
Year-over-year change
+37.3%
4-year CAGR
+10.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How AMRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +11.7% is the 5th highest of 11, against a peer median of -19.5%.
  • EBITDA amounts to 20.9% of revenue for AMRX, versus a peer median of 20.8%.
AMRX Competitors
EBITDA for AMRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026₹53.96B INR-45.2%+3.8%16.3%
VTRSViatris Inc.LTM Jun 2026$2.72B USD+650.7%—18.4%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$2.59B USD-12.9%—15.0%
BHCBausch Health Companies Inc.LTM Jun 2026$2.05B USD-37.3%+3.4%18.9%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$652.2M USD+11.7%+11.1%20.9%
INDVIndivior Pharmaceuticals IncLTM Jun 2026$437M USD+55.5%—32.8%
ANIPANI Pharmaceuticals, Inc.LTM Mar 2026$234.71M USD+251.0%+102.3%25.4%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$191.41M USD-26.2%+13.3%26.6%
EBSEmergent BioSolutions Inc.LTM Mar 2026$154.5M USD+28.1%+148.3%22.8%
CPIXCumberland Pharmaceuticals Inc.LTM Mar 2026-$1.82M USD-156.1%+107.1%4.3%
PRGOPerrigo Company plcLTM Jun 2026-$1.05B USD-271.1%—25.2%
Peer median (excluding AMRX) —-19.5%+57.8%20.8%

Competitors are the stored peer set for AMRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.09B2.21B2.39B2.79B3.02B
Cost of Revenue1.32B1.42B1.53B1.77B1.88B
Gross Profit768.97M791.46M863.87M1.02B1.14B
Gross Margin36.7%35.8%36.1%36.5%37.6%
Research & Development209.56M208.66M194.75M190.71M186.18M
Selling, General & Admin365.5M399.7M429.68M476.44M526.83M
Operating Expenses616.26M886.39M659.5M771.11M713M
Depreciation & Amortization233.41M240.18M229.4M236.19M223.57M
EBITDA401.1M440.21M500.78M439.77M603.87M
EBITDA Margin19.2%19.9%20.9%15.7%20.0%
Operating Income152.72M(94.93M)204.37M249.33M423.09M
Operating Margin7.3%-4.3%8.5%8.9%14.0%
Interest Income00000
Interest Expense136.33M158.38M210.63M258.6M241.09M
Other Income / Expenses(121.35M)(153.2M)(244.64M)(304.34M)(283.88M)
Income Before Tax31.37M(248.13M)(40.27M)(55.01M)139.21M
Pre-Tax Margin1.5%-11.2%-1.7%-2.0%4.6%
Income Tax Expense11.2M6.66M8.45M18.86M11.28M
Net Income10.62M(129.99M)(83.99M)(116.89M)72.06M
Net Margin0.5%-5.9%-3.5%-4.2%2.4%
EPS (Basic)0.07(0.86)(0.48)(0.38)0.23
EPS (Diluted)0.07(0.86)(0.48)(0.38)0.22
Weighted Avg Shares148.92M150.94M174.99M308.98M313.37M
Weighted Avg Shares (Diluted)151.82M150.94M176.14M308.98M324.81M

Amneal Pharmaceuticals, Inc.

NASDAQ:AMRX

Intrinsic Alpha fair value

Locked

Current Price

$21.88

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.